News Releases

Keyword Search

Aug-01-2019
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
Jun-10-2019
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
Jun-03-2019
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
May-15-2019
Oncternal to Present Interim Phase 1/2 Cirmtuzumab Data at ASCO
Mar-07-2019
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies
Sep-12-2018
1st Pt Dosed in Phs 1b Clinical Trial of Cirmtuzumab in Combo w/ Paclitaxel in Pts w/ Breast Cancer
Jun-01-2018
Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell
May-24-2018
Oncternal Announces Clinical Supply Arrangement to Evaluate the Combo of Cirmtuzumab and Ibrutinib
Mar-09-2018
UC San Diego Researchers Launch Combination Drug Trial to Eradicate B-Cell Malignancies
Feb-15-2018
Oncternal Opens its CIRLL Study, a Combo Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies